(4-ARYLSULFONYLAMINO)-TETRAHYDROPYRAN-4-CARBOXYLIC ACID HYDROXAMIDES

Abstract: A compound of formula (I) wherein Q is as defined, is use in the treatment of a condition selected from the group consisting of arthritis (including osteoarthritis and rheumatoid arthritis), inflammatory bowel disease, Crohn's disease, emphysema, chronic obstructive pulmonary disease, Alzheimer's disease, organ transplant toxicity, cachexia, allergic reactions, allergic contact hypersensitivity, cancer, tissue ulceration, restenosis, periodontal disease, epidermolysis bullosa, osteoporosis, loosening of artificial joint implants, atherosclerosis (including atherosclerotic plaque rupture), aortic aneurysm (including abdominal aortic aneurysm and brain aortic aneurysm), congestive heart failure, myocardial infarction, stroke, cerebral ischemia, head trauma, spinal cord injury, neuro-degenerative disorders (acute and chronic), autoimmune disorders, Huntington's disease, Parkinson's disease, migraine, depression, peripheral neurophaty, pain, cerebral amyloid angiopathy, nootropic or cognition enhancement, amyotrophic lateral sclerosis, multiple sclerosis, ocular angiogenesis, corneal injury, macular degeneration, abnormal wound healing, burns, diabetes, tumor invasion, tumor growth, tumor metastasis, corneal scarring, scleritis, AIDS, sepsis and septic shock. In addition, the compounds of the present invention may be used in combination therapy wtih standard non-steroidal anti-inflammatory drugs (NSAID'S) and analgesics, and in combination with cytotoxic drugs such as adriamycin, daunomycin, cis-platinum, etoposide, taxol, taxotere and other alkaloids, such as vincristine, in the treatment of cancer.

Description: -1- (4-ARYLSU FONYLAMINO)-TETRAHYDROPYRAN- -CARBOXYLIC ACID HYDROXAMIDES Background of the Invention The present invention relates to (4-arylsulfonylamιno)-tetrahydropyran-4-carboxylιc acid hydroxamide deπvatives , and to pharmaceutical compositions and methods of treatment The compounds of the present invention are inhibitors of zinc metalloendopeptidases, especially those belonging to the matrix metalloproteinase (also called MMP or matπxin) and reprolysin (also known as adamylsin) subfamilies of the metzincins (Rawlmgs, et al , Methods in Enzymology, 248, 183-228 (1995) and Stocker, et al , Protein Science, 4, 823-840 (1995)) The MMP subfamily of enzymes, currently contains seventeen members (MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, MMP-10, MMP-11, MMP-12, MMP-13, MMP-14, MMP-15, MMP-16, MMP-17, MMP-18, MMP-19, MMP-20) The MMP's are most well known for their role in regulating the turn-over of extracellular matrix proteins and as such play important roles in normal physiological processes such as reproduction, development and differentiation In addition, the MMP's are expressed in many pathological situations in which abnormal connective tissue turnover is occumng For example, MMP-13 an enzyme with potent activity at degrading type II collagen (the principal collagen in cartilage), has been demonstrated to be overexpressed in osteoarthπtic cartilage (Mitchell, et al , J Clin Invest , 97, 761 (1996)) Other MMPs (MMP-2, MMP-3, MMP-8, MMP-9, MMP-12) are also overexpressed in osteoarthπtic cartilage and inhibition of some or all of these MMP's is expected to slow or block the accelerated loss of cartilage typical of joint diseases such as osteoarthritis or rheumatoid arthπtis The mammalian reprolysins are known as ADAMs (A Disintegπn And Metalloproteinase) (Wolfberg, et al , J Cell Biol , 131, 275-278 (1995)) and contain a disintegπn domain in addition to a metalloproteinase-like domain To date twenty three distinct ADAM's have been identified ADAM-17, also known as tumor necrosis factor-alpha converting enzyme (TACE), is the most well known ADAM ADAM-17 (TACE) is responsible for cleavage of cell bound tumor necrosis factor-alpha (TNF-α, also known as cachectin) TNF-α is recognized to be involved in many infectious and auto-immune diseases (W Fners, FEBS Letters, 285, 199 (1991)) Furthermore, it has been shown that TNF-α is the pnme mediator of the inflammatory response seen in sepsis and septic shock (Spooner, et al_, Clinical Immunology and Immunopathology, 62 S11 (1992)) There are two forms of TNF-α, a type II membrane protein of relative molecular mass 26,000 (26 kD) and a soluble 17 kD form generated from the cell bound protein by specific proteolytic cleavage The soluble 17 kD form of TNF-α is released by the cell and is associated with the deleterious effects of TNF-α This form of -2- TNF-α is also capable of acting at sites distant from the site of synthesis Thus, inhibitors of TACE prevent the formation of soluble TNF-α and prevent the deleterious effects of the soluole factor Select compounds of the invention are potent inhibitors of aggrecanase, an enzyme important in the degradation of cartilage aggrecan Aggrecanase is also believed to be an ADAM The loss of aggrecan from the cartilage matnx is an important factor in the progression of joint diseases such as osteoarthπtis and rheumatoid arthritis and inhibition of aggrecanase is expected to slow or block the loss of cartilage in these diseases Other ADAMs that have shown expression in pathological situations include ADAM TS-1 (Kuno, et al_, J Biol Chem , 272, 556-562 (1997)), and ADAM'S 10, 12 and 15 (Wu, et al Biochem Biophys Res Comm , 235, 437-442, (1997)) As knowledge of the expression, physiological substrates and disease association of the ADAM's increases the full significance of the role of inhibition of this class of enzymes will be appreciated Diseases in which inhibition of MMP's and or ADAM's will provide therapeutic benefit include arthritis (including osteoarthπtis and rheumatoid arthπtis), inflammatory bowel disease, Crohn's disease, emphysema, acute respiratory distress syndrome, asthma chronic obstructive pulmonary disease, Alzheimer's disease, organ transplant toxrcrty, cachexia, allergic reactions, allergic contact hypersensitivity, cancer, tissue ulcerabon, restenosis, penodontal disease, epidermolysis bullosa, osteoporosis, loosening of artificial joint implants, atherosclerosis (including atherosclerotic plaque rupture), aortic aneurysm (including abdominal aortic aneurysm and brain aortic aneurysm), congestive heart failure, myocardial infarction, stroke, cerebral ischemia, head trauma, spinal cord injury, neuro-degeneratrve disorders (acute and chronic), autoimmune disorders. Huntington's disease Parkinson's disease, migraine, depression, peπpheral neuropathy, pain, cerebral amyloid angiopathy, nootropic or cognition enhancement, amyotrophic lateral sclerosis, multiple sclerosis, ocular angiogenesis, corneal injury, macular degeneration, abnormal wound healing, bums, diabetes, tumor invasion, tumor growth, tumor metastasis, corneal scarnng, scleπtis, AIDS, sepsis septic shock and other diseases characterized by metalloproteinase or ADAM expression This invention also relates to a method of using the compounds of the invention in the treatment of the above diseases in mammals, especially humans, and to the pharmaceutical compositions useful therefore It is recognized that different combinations of MMP's and ADAM's are expressed in different pathological situations As such inhibitors with specific selectivities for individual ADAM s and/or MMP's may be preferred for individual diseases For example, rheumatoid arthπtis is an inflammatory joint disease characterized by excessive TNF levels and the loss of joint matrix constituents In this case, a compound that inhibits TACE and aggrecanase as well as MMP's such as MMP-13 may be the preferred therapy In contrast, in a less inflammatory joint disease such as osteoarthπtis, compounds that inhibit matrix degrading MMP's such as MMP-13 but not TACE may be preferred The present inventors have also discovered that it is possible to design inhibitors with differential metalloprotease activity Specifically, for example, the inventors have been able to design molecules which selectively inhibit matπx metalloprotease-13 (MMP-13) preferentially over MMP-1 Matrix metalloproteinase and reprolysin inhibitors are well known in the literature Specifically, PCT Publication WO 96/33172, published October 24, 1996, refers to cyclic arylsulfonylamino hydroxamic acids that are useful as MMP inhibitors United States Patent 5,672,615, PCT Publication WO 97/20824, PCT Publication WO 98/08825, PCT publication WO 98/27069, and PCT Publication WO 98/34918, published August 13, 1998, entitled "Arylsulfonyl Hydroxamic Acid Deπvatrves" all refer to cyclic hydroxamic acids that are useful as MMP inhibitors PCT Publications WO 96/27583 and WO 98/07697, published March 7, 1996 and February 26, 1998, respectively, refer to arylsulfonyl hydroxamic acids PCT Publication WO 98/03516, published January 29, 1998 refers to phosphmates with MMP activity PCT Publication 98/34915, published August 13, 1998, entitled "N-Hydroxy-b- Sulfonyl Propionamide Deπvatives," refers to propionylhydroxamides as useful MMP inhibitors PCT Publication WO 98/33768, published August 6, 1998, entitled "Arylsulfonylamino Hydroxamic Acid Deπvatives," refers to N-unsubstituted arylsulfonylamino hydroxamic acids PCT Publication WO 98/30566, published July 16, 1998, entitled "Cyclic Sulfone Deπvatives," refers to cyclic sulfone hydroxamic acids as MMP inhibitors United States Provisional Patent Application 60/55208, filed August 8, 1997, refers to biaryl hydroxamic acids as MMP inhibitors United States Provisional Patent Application Seπal No 60/55207, filed August 8, 1997, entitled "Aryloxyarylsulfonylamino Hydroxamic Acid Derivatives," refers to aryloxyarylsulfonyl hydroxamic acids as MMP inhibitors United States Provisional Patent Application 60/62766, filed October 24, 1997, entitled 'The Use of MMP-13 Selective Inhibitors For The Treatment of Osteoarthπtis and Other MMP Mediated Disorders," refers to the use of MMP-13 selective inhibitors to treat inflammation and other disorders United States Provisional Patent Application Seπal No 60/68261, filed December 19, 1997, refers to the use of MMP inhibitors to treat angiogenesis and other disorders Each of the above referenced publications and applications is hereby incorporated by reference in its entirety -4- Summary of the Invention The present invention relates to a compound of the formula HO-N^X ' ^ SΘ^- Q I or the pharmaceutically acceptable sa 0 lts thereof, wherein Q is (C,-C 6 )alkyl, (C 6 -C 10 )aryl, (C r C 9 )heteroaryl, (C 6 -C 10 )aryloxy(C r C 6 )alkyl, (C 6 - C,o)aryloxy(C 6 -C,o)aryl, (C 6 -C 10 )aryloxy(C 2 -C 9 )heteroaryl, (C 6 -C 10 )aryl(C,-C 6 )alkyl, (C 6 - C l0 )aryl(C 6 -C 10 )aryl, (C $ -C 10 )aryl(C 2 -C 9 )heteroaryl (C 6 -C, 0 )aryl(C 6 -C,o)aryl(C,-C 6 )3lkyl, (C 6 - C,o)3ryl(C 6 -C,o)3ryl(C 6 -Cio)3ryl, (C 6 -Ci 0 )aryl(C 6 -C 10 )aryl(C 2 -C 9 )heteroaryl, (C 2 -C 9 )heteroaryl(C,- C s )alkyl, (C 2 -C 9 )heteroaryl(C 6 -C,o)aryl, (C 2 -C 9 )heteroaryl(C 2 -C 9 )heteroaryl, (C 6 -C,o)aryl(C r C 6 )alkoxy(C,-C 6 )alkyl, (C 6 -C,o)aryl(C 1 -C 6 )alkoxy(C 6 -C 1 o)aryl, (C f rC^ary CrCβJalkoxyfC C 9 )heteroaryl, (C 2 -C 9 )heteroaryloxy(C,-C 6 )alkyl, (C 2 -C 5 )heteroaryloxy(C 6 -C 10 )aryl, (C 2 - C 9 )heteroaryloxy(C 2 -C 9 )heteroaryl, (C 2 -C 9 )heteroaryl(C 1 -C 6 )alkoxy(C 1 -C 6 )alkyl, (C 2 - C 9 )heteroaryl(C 1 -C 6 )alkoxy(C 6 -C,o)aryl or (C 2 -C 9 )heteroaryl(Cι-C 3 )alkoxy(C 2 -C 9 )heteroaryl; wherein each (C 6 -Cι 0 )aryl or (C 2 -C 9 )hetero3ryl moieties of said (C 6 -Ci 0 )aryl, (C 2 - C 9 )heteroaryl, (C 6 -Cι 0 )aryloxy(Cι-C 6 )alkyl, (Cs-C^aryloxyfCβ-C^aryl, (C 6 -C, 0 )aryloxy(C 2 - C 9 )heteroaryl, (C 6 -C, 0 )aryl(C,-C 6 )alkyl, (C 6 -Cιo)3ryl(C 6 -C 10 )aryl, (C 6 -Ci 0 )aryl(C 2 -C 9 )heteroaryl, (C 6 -C 10 )aryl(C 6 -Cio)aryl(C,-C 6 )alkyl, (C 6 -C, 0 )aryl(C 6 -Cιo)aryl(C 6 -C, 0 )aryl, (C 6 -C, 0 )aryl(C 6 - Cio)aryl(C 2 -C 9 )heteroaryl, (C 2 -C 9 )heteroaryl(C,-C 3 )alkyl, (C 2 -C 9 )hetero3ryl(C 6 -C 10 )aryl, (C 2 - C 9 )heteroaryl(C 2 -C 9 )heteroaryl, (C 6 -C,o)aryl(C 1 -C 6 )3lkoxy(C 1 -C 6 )alkyl, (Cg-C^ary C,- C 6 )alkoxy(C 6 -C, 0 )aryl, (C 6 -Cιo)3ryl(Cι-C 6 )3lkoxy(C 2 -C 9 )hetero3ryl, (C 2 -C 9 )heteroaryloxy(C r C 6 )alkyl, (C 2 -C 9 )heteroaryloxy(C 6 -C, 0 )aryl, (C 2 -C 9 )heteroaryloxy(C 2 -C 9 )heteroaryl, (C 2 - C 9 )hetero3ryl(C 1 -C 6 )3lkoxy(C 1 -C 6 )3lkyl, (C 2 -C 9 )hetero3ryl(C,-C 6 )alkoxy(C 6 -C 10 )aryl or (C 2 - C 9 )hetero3ryl(C,-C 6 )3lkoxy(C 2 -C 9 )hetero3ryl is optionally substituted on any of the πng carbon atoms capable of forming an additionsl bond by one or more substituents per πng independently selected from ftuoro, chloro, bromo, (C,-C 6 )alkyl, (^-CβJalko y, perfluoro(C,-C 3 )alkyl, perfluoro(C,-C 3 )alkoxy and (C 6 -C 10 )aryloxy, or s pharmaceutically acceptable salt thereof The term "alkyl", as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight, branched or cyclic moieties or combinations thereof The term "alkoxy", ss used herein, includes O-alkyl groups wherein "alkyl" is defined above -5- The term "aryl", as used herein, unless otherwise indicated, includes an organic radical deπved from an aromatic hydrocarbon by removal of one hydrogen, such as phenyl or naphthyl, optionally substituted by 1 to 3 substituents selected from the group consisting of fluoro, chloro, bromo, perfluoro(C,-C 6 )alkyl (including tπfluoromethyl), (C,-C 6 )alkoxy, (C 6 -C, 0 )aryloxy, perfluoro(C,-C 3 )alkoxy (including tπfluorcmethoxy and difiuoromethoxy) and (C,-C 6 )alkyl The term "heteroaryl", as used herein, unless otherwise indicated, includes an organic radical derived from an aromatic heterocyclic compound by removal of one hydrogen, such as pyπdyl, furyl, pyrroyl, thienyl, isothiazoryl, imidazolyl, benzimidazolyl, tetrazolyl, pyrazinyl, pyπmidyl, quinolyl, isoquinolyl, benzofuryl, isobenzofuryl, benzothienyl, pyrazolyl, indolyl, isomdolyl, puπnyl, carbazolyl, isoxazolyl thiazolyl, oxazolyl, benzthiazolyl or benzoxazolyl, optionally substituted by 1 to 2 substituents selected from the group consisting of fluoro, chloro, tπfluoromethyl, (C,-C 6 )alkoxy, (C 6 -C 10 )aryloxy, tπfluoromethoxy, difiuoromethoxy and (C,- C 6 )3lkyl Preferred heteroaryls include pyridyl, furyl, thienyl, isothiazolyl, pyrazinyl, pyπmidyl, pyrazolyl, isoxazolyl, thiazolyl or oxazolyl Most preferred include pyπdyl, furyl or thienyl. Preferred compounds of formula I include those wherein Q is optionally substituted (C 6 - C, 0 )aryl, (C 6 -C, 0 )aryl(C 6 -C,o)aryl, (Cs-C.^aryloxyfCs-C^aryl, (C 6 -C 10 )aryloxy(C 2 -C 9 )heteroaryl, (C 2 -C 9 )heteroaryl, (C 2 -C 9 )heteroaryl(C 2 -C 9 )heteroaryl, (C 6 -C, 0 )aryl(C 2 -C 9 )heteroaryl, (C 2 - C 9 )heteroaryl(C 6 -C 10 )aryl, (C 2 -C 9 )heteroaryloxy(C 6 -C 10 )aryl, (C 6 -C,o)aryl(Cι-C 6 )alkoxy(C 6 - C, 0 )aryl, or (C 2 -C 9 )heteroaryl(C,-C 6 )3lkoxy(C 6 -C,o)aryl. Other preferred compounds of formula I include those wherein Q is optionally substituted (C 6 -C,o)aryloxy(C 6 -C,o)3ryl Specific preferred compounds of formula I include the following 4-[4-(4-Fluorophenoxy)benzenesulfonylamιno]tetr3hydropyran-4-carboxylιc acid hydroxyamide, 4-[4-(4-Chlorophenoxy)benzenesulfonylamino]tetrahydropyran-4-carboxylic acid hydroxyamide, 4-[4-(Phenoxy)benzenesulfonylamιno]tetrahydropyran-4-carboxylιc acid hydroxyamide, 4-[4-(4-Pyrιdyloxy)benzenesulfonylamιno]tetrahydropyran-4-c3rboxylιc acid hydroxyamide, 4-[4-(4-Fluorophenyl)benzenesurfonylamιno]tetrahydropyran-4-carboxylιc acid hydroxyamide, 4-[4-(4-Fluorophenylmethoxy)bezenesulfonylamιno]tetrahydropyran-4-carboxylιc acid hydroxyamide; 4-[4-(Phenylmethoxy)benzenesulfonylamιno]tetrahydropyran-4-carboxylιc acid hydroxyamide; and -6- 4-[4-(4-Fluorophenylethoxy)benzenesulfonylamιno]tetrahydropyran-4-carboxylιc acid hydroxyamide The present invention also relates to a pharmaceutical composition for the treatment of a condition selected from the group consisting of arthritis (including osteoarthπtis and rheumatoid arthπtis), inflammatory bowel disease, Crohn's disease, emphysema, chronic obstructive pulmonary disease, Alzheimer's disease, organ transplant toxicity, cachexia, allergic reactions allergic contact hypersensitivity, cancer (such as solid tumor cancer including colon cancer breast cancer, lung cancer and prostrate cancer and hematopoietic malignancies including leukemias and lymphomas), tissue ulceration, restenosis, peπodontal disease, epidermolysis bullosa, osteoporosis, loosening of artificial joint implants, atherosclerosis (including atherosclerotic plaque rupture), aortic aneurysm (including abdominal aortic aneurysm and brain aortic aneurysm), congestive heart failure, myocardial infarction, stroke, cerebral ischemia, head trauma, spinal cord injury, neuro-degenerative disorders (acute and chronic), autoimmune disorders, Huntington's disease, Parkinson's disease, migraine, depression, penpheral neuropathy, pain, cerebral amyloid angiopathy nootropic or cognition enhancement amyotrophic lateral sclerosis, multiple sclerosis, ocular angiogenesis, corneal injury, maculsr degeneration, abnormal wound healing, bums, diabetes, tumor invasion, tumor growth, tumor metastasis, corneal scamng, sclentis, AIDS, sepsis, septic shock and other diseases characterized by metalloproteinase activity and other diseases characterized by mammalian reprolysm activity in a mammal, including a human compπsmg an amount of a compound of formula I or a pharmaceutically acceptable salt thereof effective in such treatments and a pharmaceutically acceptable earner The present invention also relates to a pharmaceutical composition for the inhibition of (a) matπx metalloproteinases or other metalloproteinases involved in matπx degradation, or (b) a mamma sn reprolysm (such as aggrecanase or ADAM's TS-1 , 10, 12, 15 and 17, most preferably ADAM-17) in a mammal, including a human, compπsing an effective amount of a compound of formula I or a pharmaceutically acceptable sslt thereof The present invention also relates to a mefrod for treating a condition selected from the group consisting of arthπtis (including osteoarthπtis and rheumatoid arthπtis), inflammatory bowel disease, Crohn's disease, emphysema, chronic obstructive pulmonary disease, Alzheimer's disease, organ transplant toxicity, cachexia, allergic reactions, allergic contact hypersensitivity, cancer, tissue ulceration, restenosis, peπodontal disease, epidermolysis bullosa, osteoporosis loosening of artificial joint implants, atherosclerosis (including atherosclerotic plaque rupture) aortic aneurysm (including abdominal aortic aneurysm and brain aortic aneurysm), congestive heart failure, myocardisl infarction, stroke, cerebral ischemia, head trauma, spinal cord injury neuro-degeneratrve disorders (acute and chronic), autoimmune disorders, Huntington's disease -7- Parkinson's disease, migraine depression, peripheral neuropathy, pain, cerebral amyloid angiopathy, nootropic or cognition enhancement, amyotrophic lateral sclerosis, multiple sclerosis, ocular angiogenesis corneal injury, maculsr degeneration, abnormal wound healing, bums diabetes, tumor invasion tumor growth, tumor metastasis, corneal scamng, scleπtis, AIDS sepsis, septic shock and other diseases characterized by metalloproteinase activity and other diseases characterized by mammalian reprolysm activity in a mammal, including a human, compπsing administeπng to said mammal an amount of a compound of formula I or a pharmaceutically acceptable salt thereof effective in treating such a condition The present invention also relates to a method for the inhibition of (a) matπx metalloproteinases or other metalloproteinases involved in matπx degradation or (b) a mammalian reprolysm (such as aggrecanase or ADAM's TS-1, 10, 12, 15 and 17, preferably ADAM-17) in a mammal, including a human, compπsing administeπng to said mammal an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof This invention also encompssses pharmaceutical compositions containing prodrugs of compounds of the formula I This invention also encompasses methods of treating or preventing disorders that can be treated or prevented by the inhibition of matπx metalloproteinases or the inhibition of mammalian reprolysm compπsing administeπng prodrugs of compounds of the formula I Compounds of formula I having free am o, amido, hydroxy or carboxylic groups can be converted into prodrugs Prodrugs include compounds wherein an ammo acid residue, or a polypeptide chain of two or more (e g , two, three or four) ammo acid residues which are covalently joined through pepbde bonds to free ammo, hydroxy or carboxylic acid groups of compounds of formula I The ammo acid residues include the 20 naturally occumng ammo acids commonly designated by three letter symbols and also include, 4-hydroxyprolιne, hydroxylysine, demosme, isodemosine, 3-methylhιstιdιne, norvahn, beta-alanme, gamma-ammobutyπc acid, citrulline, homocysteme, homoseπne, omrthine snd methionme sulfone Prodrugs also include compounds wherein carbonates, carbamates, amides and alkyl esters which are covalently bonded to the above substituents of formula I through the carbonyl carbon prodrug sidecham One of ordinary skill in the art will appreciate that the compounds of the invention are useful in treating a diverse array of diseases One of ordinary skill in the art will also appreciste that when using the compounds of the invention in the treatment of a specific disease that the compounds of the invention may be combined with vaπous existing therapeutic agents used for that disease For the treatment of rheumatoid arthritis, the compounds of the invention may be combined with agents such as TNF-α inhibitors such as anti-TNF monoclonal antibodies and TNF receptor immunoglobulin molecules (such as Enbrel®), low dose methotrexate, lefunimide, hydroxychloroquine, d-peniαlamine, auranofin or parenteral or oral gold -8- The compounds of the invention can also be used in combination with existing therapeutic agents for the treatment of osteoarthritis Suitable agents to be used in combination include standard non-steroidal anti-inflammatory agents (hereinafter NSAID's) such as piroxicam, diclofenac, propionic acids such as naproxen, flubiprofen, fenoprofen, ketoprofen and ibuprofen, fenamates such as mefenamic acid, indomethacin, sulindac, apazone, pyrazolones such as phenylbutazone, salicylates such as aspirin, COX-2 inhibitors such as celecoxib and rofecoxib, analgesics and intraarticular therapies such as corticosteroids and hyaluronic acids such as hyalgan and synvisc. The compounds of the present invention may also be used in combination with anticancer agents such as endostatin and angiostatin or cytotoxic drugs such as adriamycin, daunomycin, cis-platmum, etoposide, taxol, taxotere and alkaloids, such as vmcπstine, and antimetabolites such as methotrexate. The compounds of the present invention may also be used in combination with cardiovascular agents such as calcium channel blockers, lipid lowering agents such as statins, fibrates, beta-blockers, Ace inhibitors, Angιotensin-2 receptor antagonists and platelet aggregation inhibitors. The compounds of the present invention may also be used in combination with CNS agents such as antidepressants (such as sertraline), anti-Parkinsonian drugs (such as deprenyl, L-dopa, requip, miratex, MAOB inhibitors such as selegme and rasagiline, comP inhibitors such as Tasmar, A-2 inhibitors, dopamme reuptake inhibitors, NMDA antagonists, Nicotine agonists, Dopamme agonists and inhibitors of neuronal nitric oxide synthase), and anti-Alzheimer's drugs such as Aπcept, tacπne, COX-2 inhibitors, propentofylline or metryfonate The compounds of the present invention may also be used in combination with osteoporosis agents such as droloxifene or fosomax and immunosuppressant agents such as FK-506 and rapamycin Detailed Descπption of the Invention The following reaction Scheme illustrates the preparation of the compounds of the present invention. Unless otherwise indicated, Q in the reaction Schemes and the discussion that follows is defined as above Scheme 1 -10- Scheme 1 (continued) -11 - Scheme 1 refers to the preparation of compounds of the formula I Refemng to Scheme 1, the compound of formula I is prepared from the carboxylic acid of formula II by treatment with 1-(3-dιmethylamιnopropyl)-3-ethylcart)θdιιmιde and 1- hydroxybenztπazole in a polar solvent, such as N N-dimethylformamide, followed by the addition of hydroxylamme to the reaction mixture after a time peπod between about 15 minutes to about 1 hour, preferably about 30 minutes The hydroxylamme is preferably generated in situ from a salt form, such as hydroxylamme hydrochlonde, in the presence of a base, such as tπethylamine Alternatively the compound of formula I can be prepared from a compound of formula II by reaction with a protected deπvative of hydroxylamme or its salt form, where the hydroxyl group is protected as a tert-butyl, benzyl, allyl or 2-tπmethylsιlylethyl ether Removal of the hydroxyl protecting group is earned out by hydrogenolysis for a benzyl protecting group (5% palladium on baπum sulfate is the preferred catalyst) or treatment with a strong acid, such as tπfluoroacetic acid, for a tert-butyl protecting group The allyl protecting group may be removed by treatment with tnbutylbnhydπde and acetic acid in the presence of catalybc bιs(tπphenylphosphιne) palladιum(ll)chlonde The 2-tπmethylsιlylethyl ether may be removed by reaction with a strong acid such as tπfluoroacetic acid or by reaction with a fluoπde source such as boron tπfluoπde etherate The reaction of II with hydroxylamme, a salt of hydroxylamme, a protected deπvative of hydroxylamme or a salt of a protected deπvative of hydroxylamme may also be earned out in the presence of (benztπazol-1-yloxy)tπs(dιmethylamιno)-phosphonιum hexafluorophosphate and a base such as tπethylam e in an inert solvent, such as methylene chloπde The reaction mixture is stirred at a temperature between about 0°C to about 50°C, preferably room temperature, for a time peπod between about 1 hour to about 3 days, preferably about 1 day Another procedure for converting a compound of formula II to a compound of formula I is to react the compound of formula II with O-benzylhydroxylamine hydrochlonde in the presence of (benztπazol-1-yloxy)tπs(dιmethylamιno)phosphonιum hexafluorophosphate and tπethylamine using methylene chloπde as solvent Subsequent removal of the O-benzyl protecting group to afford a compound of formula I is then earned out by hydrogenolysis under 3 atmospheres hydrogen at room temperature using 5% palladium on baπum sulfate as catalyst The preferred solvent is methanol The reaction time may vary from about 1 hour to about 2 days (8 hours is preferred) The preferred procedure for converting a compound of formula II to a compound of formula I is to react the compound of formula II with oxalyl chloπde in methylene chloπde in the presence of a catalytic amount of DMF for 16 hours The resulting acid chloπde is reacted at 0°C with N, O- bis tnmethylsilyl hydroxylamme formed by reacting hydroxyamine hydrochlonde with chlorotπmethyl-silane in pyπdine at 0°C to room temperature The product of formula I is -12- obtained after a few hours reacbons at 0°C to room temperature followed by an acidic aqueous workup which removes all tπmethyl silyl residues In certain instances it is preferred to obtain the compound of formula I by reaction of hydroxylamme, a salt of hydroxylamme, a protected derivative of hydroxylamme or a salt of a protected deπvabve of hydroxylamme with an activated ester of formula III The reaction is camed out in an inert solvent, such as N,N-dιmethyl-formamιde at a temperature ranging from about room temperature to about 80°C, preferably about 60°C for a time peπod of about 1 hour to about 2 days If a protected denvative of hydroxylamme or a salt of a protected deπvative of hydroxylamme is used, removal of the protecting group is camed out as described above The activated ester deπvative of formula III is obtained by treatment of the compound of formula II with (benztnazol-1-yloxy)tπs(dιmethylamιno)-phosphonιum hexafluorophosphate and a base such as tnethylamine in an inert solvent, such as methylene chlonde The reaction mixture is sti ed at a temperature between about 0°C to about 50°C, preferably room temperature, for a time peπod between about 1 hour to about 3 days, preferably about 1 day The intermediate compound of formula II is prepared by saponificabon of a compound of formula IV. The reacbon is camed out at in a solvent, such as aqueous ethanol, with an excess of a metal hydroxides, such as sodium hydroxide or lithium hydroxide, at a temperature of about 20° C to about 100° C, (i β room temperature to the reflux temperature of the solvent), preferably about 80° C The reacbon mixture is normally agitated at room temperature for a bme peπod between about 30 minutes to about 1 week, preferably about 16 hours The compound of formula IV is prepared by reacbng a compound of formula V with a reactive funcbonal deπvabve of a sulfonic acid (QS0 2 OH), such as the sulfonyl chloπde (QS0 2 CI) in the presence of a base Suitable bases include sodium hydroxide, tπethylamine or diisopropylethylamine, preferably tπethylamine Suitable solvents include dimethylformamide (DMF), methylene chloπde, tetrahydrofuran, dioxane, water or acetonitπle, preferably DMF The reaction mixture is stirred at a temperature between about 0°C to about 50°C, preferably at about 20°C to about 25°C (i e room temperature), for a time peπod between about 10 minutes to about 2 days, preferably about 1 day The compound of formula V is prepared by hydrolysis of a compound of formula IV Specifically, the compound of formula VI is treated with aqueous acid, preferably in the presence of an immiscible organic solvent such ethyl ether, dnsopropyl ether or methylene chloπde Suitable acids include hydrochbπc and sulfuπc The reacbon mixture is starred at a temperature between about 0°C to about 50°C, preferably at about 20°C to about 25°C (t e room temperature), for a bme peπod between about 10 minutes to about 2 days, preferably about 1 day The compound of formula VI is prepared by reacbon of the ammo acid deπvative of the formula VII with a compound of the formula VIII in the presence of a base and a solvent, wherein X is Cl, Br, I, tosylate or mesylate Suitable bases include ethlyene glycol, sodium hydπde, lithium diisopropylamtde, or sodium hexamethyl disilazide Suitable solvents include dimethylether, dimethylformamide, tetrahydrofuran or dimethylsulfoxide The reacbon mixture is sbrred at a temperature between about -20°C to about 25 β C, preferably at about 0 β C to about 20°C (i β room temperature), for a bme peπod between about 10 minutes to about 2 days, preferably about 1 day The compounds of formulae VII and VIII can be prepared by methods well known to those of ordinary skill in the art Examples of such compounds include methylglyαne beπzophenone imine and ethyl glycine benzophenone imine Pharmaceutically acceptable salts of the acidic compounds of the invenbon are salts formed with bases, namely cabonic salts such as alkali and alkaline earth metal salts, such as sodium, lithium, potassium, calcium, magnesium, as well as ammonium salts, such as ammonium, tπmethyl-ammonium, diethylammonium, and tπs-(hydroxymethyl)-methylammonιum slats Similarly acid addibon salts, such as of mineral acids, organic carboxylic and organic sulfonic acids e g hydrochloric acid, methanesuffonic acid, maleic acid, are also possible provided a basic group, such as pyπdyl, constitutes part of the structure The ability of the compounds of formula I or their pharmaceubcally acceptable salts (hereinafter also referred to as the compounds of the present invenbon) to inhibit metalloproteinases or mammalian reprolysm and, consequently, demonstrate their effecbveness for treating diseases characterized by metalloproteinase or the production of tumor necrosis factor is shown by the following in vitro assay tests Biological Assay Inhibition of Human Collagenase (MMP-1) Human recombinant collagenase is activated with trypsin The amount of trypsin is opbmized for each lot of collagenase-1 but a typical reacbon uses the following rabo 5 μg trypsin per 100 μg of collagenase The trypsin and collagenase are incubated at room temperature for 10 minutes then a five fold excess (50 mg/10 mg trypsin) of soybean trypsin inhibitor is added Stock solubons (10 mM) of inhibitors are made up in dimethylsulfoxide and then diluted using the following scheme 10 mM > 120 μM > 12 μM > 1 2 μM > 0 12 μM Twenty-five microliters of each concentration is then added in tπplicate to appropπate wells of a 96 well microfluor plate The final concentration of inhibitor will be a 1 4 dilution after -14- addition of enzyme and substrate Positive controls (enzyme, no inhibitor) are set up in wells D7-D12 and negative controls (no enzyme, no inhibitors) are set in wells D1-D6 Collagenase-1 is diluted to 240 ng/ml and 25 ml is then added to appropnate wells of the microfluor plate Final concentration of collagenase in the assay is 60 ng/ml Substrate (DNP-Pro-Cha-Gly-Cys(Me)-Hιs-Ala-Lys(NMA)-NH 2 ) is made as a 5 mM stock in dimethylsulfoxide and then diluted to 20 μM in assay buffer The assay is initiated by the addibon of 50 ml substrate per well of the microfluor plate to give a final concentrabon of 10 mM Fluorescence readings (360 nM excitabon, 460 nm emission) are taken at time 0 and then at 20 minute intervals The assay is conducted at room temperature with a typical assay time of 3 hours Fluorescence versus bme is then plotted for both the blank and collagenase containing samples (data from tπplicate determinations is averaged) A bme point that provides a good signal (at least five fold over the blank) and that is on a linear part of the curve (usually around 120 minutes) is chosen to determine IC 50 values The zero bme is used as a blank for each compound at each concentrabon and these values are subtracted from the 120 minute data. Data is plotted as inhibitor concentrabon versus % control (inhibitor fluorescence divided by fluorescence of collagenase alone x 100) ICso's are determined from the concentration of inhibitor that gives a signal that is 50% of the control If IC^'s are reported to be less than 0 03 mM then the inhibitors are assayed at concentrations of 0 3 mM, 003 mM, and 0.003 mM Inhibition of Gelabnase (MMP-2) Human recombinant 72 kD gelatinase (MMP-2, gela nase A) is acbvated for 16-18 hours with 1mM p-aminophenyl-mercuric acetate (from a freshly prepared 100 mM stock in 0 2 N NaOH) at 4°C, rocking gently 10 mM dimethylsulfoxide stock solutions of inhibitors are diluted seπally in assay buffer (50 mM TRIS. pH 7 5, 200 mM NaCI, 5 mM CaCI 2 20 μM ZnCI 2 and 0 02% BRIJ-35 (vol /vol )) using the following scheme 10 mM — * 120 μM > 12 μM > 1 2 μM 0.12 μM Further dilutions are made as necessary following this same scheme A minimum of four inhibitor concentrabons for each compound are performed in each assay 25 μL of each concentration is then added to triplicate wells of a black 96 well U-bottomed microfluor plate As the final assay volume is 100 μL, final concentrations of inhibitor are the result of a further 1 4 dilution (i e 30 μM — * 3 μM — ► 0 3 μM — > 0 03 μM, etc ) A blank (no enzyme, no inhibitor) and a positive enzyme control (with enzyme, no inhibitor) are also prepared in triplicate -15- Activated enzyme is diluted to 100 ng/mL in assay buffer, 25 μL per well is added to appropπate wells of the microplate Final enzyme concentration in the assay is 25 ng/mL (0 34 nM) A five mM dimethylsulfoxide stock solution of substrate (Mca-Pro-Leu-Gly-Leu-Dpa- Ala-Arg-NH 2 ) is diluted in assay buffer to 20 μM The assay is initiated by addition of 50 μL of diluted substrate yielding a final assay concentration of 10 μM substrate At bme zero, fluorescence reading (320 excitation, 390 emission) is immediately taken and subsequent readings are taken every fifteen minutes at room temperature with a PerSeptive Biosystems CytoFluor Multi-Well Plate Reader with the gain at 90 units The average value of fluorescence of the enzyme and blank are plotted versus time An early time point on the linear part of this curve is chosen for ICso determinations The zero time point for each compound at each dilution is subtracted from the latter time point and the data then expressed as percent of enzyme control (inhibitor fluorescence divided by fluorescence of positive enzyme control x 100) Data is plotted as inhibitor concentrabon versus percent of enzyme control ICso's are defined as the concentrabon of inhibitor that gives a signal that is 50% of the positive enzyme control Inhibibon of Stromelysin Activity (MMP-3) Human recombinant stromelysin (MMP-3, stromelysιn-1) is acbvated for 20-22 hours with 2 mM p-aminophenyl-mercuπc acetate (from a freshly prepared 100 mM stock in 0 2 N NaOH) at 37°C 10 mM dimethylsulfoxide stock solutions of inhibitors are diluted serially in assay buffer (50 mM TRIS, pH 7 5, 150 mM NaCI, 10 mM CaCI 2 and 0 05% BRIJ-35 (vol /vol )) using the following scheme 10 mM-→ 120 μM ► 12 μM 1 2 μM > 0 12 μM Further dilutions are made as necessary following this same scheme A minimum of four inhibitor concentrabons for each compound are performed in each assay 25 μL of each concentration is then added to triplicate wells of a black 96 well U-bottomed microfluor plate As the final assay volume is 100 μL, final concentrations of inhibitor are the result of a further 1 4 dilution (i e 30 μM — ► 3 μM — ► 0 3 μM > 0 03 μM, etc ) A blank (no enzyme, no inhibitor) and a positive enzyme control (with enzyme, no inhibitor) are also prepared in triplicate Activated enzyme is diluted to 200 ng/mL in assay buffer, 25 μL per well is added to appropπate wells of the microplate Final enzyme concentration in the assay is 50 ng/mL (0 875 nM) A ten mM dimethylsulfoxide stock solution of substrate (Mca-Arg-Pro-Lys-Pro-Val- Glu-Nva-Trp-Arg-Lys(Dnp)-NH 2 ) is diluted in assay buffer to 6 μM The assay is initiated by -16- addition of 50 μL of diluted substrate yielding a final assay concentrabon of 3 μM substrate At time zero, fluorescence reading (320 excitation, 390 emission) is immediately taken and subsequent readings are taken every fifteen minutes at room temperature with a PerSeptive Biosystems CytoFluor Multi-Well Plate Reader with the gain at 90 units The average value of fluorescence of the enzyme and blank are plotted versus time An early time point on the linear part of this curve is chosen for IC 50 determinations The zero time point for each compound at each dilution is subtracted from the latter time point and the data then expressed as percent of enzyme control (inhibitor fluorescence divided by fluorescence of positive enzyme control x 100) Data is plotted as inhibitor concentration versus percent of enzyme control IC^'s are defined as the concentrabon of inhibitor that gives a signal that is 50% of the positive enzyme control Inhibition of MMP-13 Human recombinant MMP-13 is activated with 2mM APMA (p-aminophenyl mercuπc acetate) for 2 0 hours, at 37°C and is diluted to 240 ng/ml in assay buffer (50 mM Tπs, pH 7 5, 200 mM sodium chloπde, 5mM calcium chloπde, 20mM zinc chloπde, 002% bπj 35) Twenty- five microliters of diluted enzyme is added per well of a 96 well microfluor plate The enzyme is then diluted in a 1 4 ratio in the assay by the addibon of inhibitor and substrate to give a final concentrabon in the assay of 60 ng/ml Stock solubons (10 mM) of inhibitors are made up in dimethylsulfoxide and then diluted in assay buffer as per the inhibitor dilubon scheme for inhibibon of human collagenase -1 (MMP- 1) Twenty-five microliters of each concentrabon is added in tπp cate to the microfluor plate The final concentrabons in the assay are 30 mM, 3mmM, 0 3m mM, and 0 03 mmM Substrate (Dnp-Pro-Cha-Gly-Cys(Me)-Hιs-Ala-Lys(NMA)-NH 2 ) is prepared as for inhibition of human collagenase (MMP-1) and 50 μl is added to each well to give a final assay concentrabon of 10 μM Fluorescence readings (360 nM exαtabon, 450 nM emission) are taken at time 0 and every 5 minutes for 1 hour Positive controls and negative controls are set up in tπplicate as outlined in the MMP-1 assay ICso's are determined as per inhibibon of human collagenase (MMP-1) If ICso's are reported to be less than 0 03 mM, inhibitors are then assayed at final concentrabons of 0 3 mM, 0 03 mmM, 0003 mmM and 00003 mM Inhibition of TNF Production The ability of the compounds or the pharmaceutically acceptable salts thereof to inhibit the production of TNF and, consequently, demonstrate their effecbveness for treating diseases involving the production of TNF is shown by the following in vitro assay Human mononuclear cells were isolated from anb-coagulated human blood using a one- step Ficoll-hypaque separabon technique (2) The mononuclear cells were washed three bmes in Hanks balanced salt solubon (HBSS) with divalent cations and resuspended to a density of 2 x 10 6 /ml in HBSS containing 1% BSA. Differenbal counts determined using the Abbott Cell Dyn 3500 analyzer indicated that monocytes ranged from 17 to 24% of the total cells in these preparations 180 μl of the cell suspension was aliquoted into flat bottom 96 well plates (Costar) Addrbons of compounds and LPS (100 ng/ml final concentrabon) gave a final volume of 200 μl All conditions were performed in tnplicate After a four hour incubabon at 37°C in an humidified C0 2 incubator, plates were removed and centπfuged (10 minutes at approximately 250 x g) and the supematants removed and assayed for TNFa using the R&D ELISA Kit Inhibibon of Soluble TNF-α Production The ability of the compounds or the pharmaceubcally acceptable salts thereof to inhibit the cellular release of TNF-α and, consequently, demonstrate their effectiveness for treahng diseases involving the disregulabon of soluble TNF-α is shown by the following in vitro assay Method for the evaluation of recombinant TNF-α Converting Enzyme Activity Expression of recombinant TACE A DNA fragment coding for the signal sequence, preprodomain, prodomain and catalytic domain of TACE (ammo acids 1-473), can be amplified by polymerase chain reacbon using a human lung cDNA library as a template The amplified fragment is then cloned into pFastBac vector The DNA sequence of the insert is confirmed for both the strands A bacmid prepared using pFastBac in E coli DHIOBac is transfected into SF9 insect cells The virus particles is then amplified to P1, P2, P3 stages The P3 virus is infected into both Sf9 and High Five insect cells and grown at 27°C for 48 hours The medium is collected and used for assays and further purification Preparation of fluorescent quenched substrate A model peptidic TNF-α substrate (LY-LeuαneAlanineGlutamineAlanineVa ne- ArgιnιneSeπne-SeπneLysιne(CTMR)-Argιnιne (LY=Lucιfer Yellow, CTMR=Carboxytetramethyl-Rhodamιne)) is prepared and the concentration estimated by absorbance at 560 nm (E56O. 60,000 M-1CM-1) according to the method of Geoghegan, KF, "Improved method for converting an unmodified pepbde to an energy-transfer substrate for a - 10- proteinase " Bioconjugate Chem. 7, 385-391 (1995). This pepbde encompasses the cleavage cite on pro-TNF wh.ch is cleaved in vivo by TACE. Expression of reco oinant TACE A DNA fragment coding for the signal sequence, preprodomam, prodomain and catalytic domain of TACE (am o acids 1-473), is amplified by polymerase chain reaction using a human lung cDNA library as a template. The amplified fragment is cloned into pFastBac vector The DNA sequence of the insert is confirmed for both the strands. A bacmid prepared using pFastBac in E. coli DHIOBac is transfected into SF9 insect cells. The virus particles were amplified to P1 , P2, P3 stages. The P3 virus is infected into both Sf9 and High Five insect cells and grown at 27 β C for 48 hours. The medium is collected and used for assays and further purification Enzyme reaction. The reaction, earned out in a 96 well plate (Dynatech), is comprised of 70 μl of buffer solution (25 mM Hepes-HCI, pH7.5, plus 20 uM ZnCI 2 ), 10 μl of 100 μM fluorescent quenched substrate, 10 μl of a DMSO (5%) solution of test compound, and an amount of r-TACE enzyme which will cause 50% cleavage in 60 minutes - in a total volume of 100 μl. The specificity of the enzyme cleavage at the amide bond between alanine and valine is verified by HPLC and mass spectrometry. Initial rates of cleavage are monitored by measuring the rate of increase in fluorescence at 530 nm (excitation at 409 nm) over 30 minutes. The experiment is controlled as follows' 1) for background fluorescence of substrate; 2) for fluorescence of fully cleaved substrate; 3) for fluorescence quenching or augmentation from solutions containing test compound. Data is analyzed as follows. The rates from the non-test compound containing "control" reactions were averaged to establish the 100% value The rate of reaction in the presence of test compound was compared to that in the absence of compound, and tabulated as "percent of non-test compound containing control. The results are plotted as "% of control" vs. the log of compound concentration and a half-maximal point or IC 50 value determined. All of the compounds of the invention have IC 50 of less than 1 μM, preferably less than 50nM. Most preferred compounds of the invention are at least 100 fold less potent against r- MMP-1 than in the above TACE assay. Human Monocyte Assay Human mononuclear cells are isolated from anb-coagulated human blood using a one- step Ficoll-hypaque separabon technique. (2) The mononuclear cells are washed three times in Hanks balanced salt solubon (HBSS) with divalent cations and resuspended to a density of 2 x 10 6 /ml in HBSS containing 1% BSA. Differential counts determined using the Abbott Cell Dyn -19- 3500 analyzer indicated that monocytes ranged from 17 to 24% of the total cells in these preparations 180m of the cell suspension was aliquoted into flat bottom 96 well plates (Costar) Additions of compounds and LPS (100 ng/ml final concentration) gave a final volume of 200 μl All condibons were performed in tnplicate After a four hour incubation at 37 β C in an humidified C0 2 incubator, plates were removed and centπfuged (10 minutes at approximately 250 x g) and the supematants removed and assayed for TNF-α using the R&D ELISA Kit. Aggrecanase Assay Pπmary porcine chondrocytes from articular joint cartilage are isolated by sequential trypsin and collagenase digestion followed by collagenase digestion overnight and are plated at 2 X 10 5 cells per well into 48 well plates with 5 μCi / ml 35 S (1000 Cι/mmol) sulphur in type I collagen coated plates Cells are allowed to incorporate label into their proteoglycan matπx (approximately 1 week) at 37°C, under an atmosphere of 5% C0 2 . The night before initiating the assay, chondrocyte monolayers are washed two times in DMEM 1% PSF/G and then allowed to incubate in fresh DMEM /1% FBS overnight. The following morning chondrocytes are washed once in DMEM/1%PSF/G The final wash is allowed to sit on the plates in the incubator while making dilutions. Media and dilutions can be made as descnbed in the Table below. Control Media DMEM alone (control media) IL-1 Media DMEM + IL-1 (5 ng/ml) Drug Dilutions Make all compounds stocks at 10 mM in DMSO. Make a 100 uM stock of each compound in DMEM in 96 well plate Store in freezer overnight The next day perform seπal dilutions in DMEM with IL-1 to 5 uM, 500 nM and 50 nM Aspirate final wash from wells and add 50 ul of compound from above dilutions to 450 ul of IL-1 media in appropπate wells of the 48 well plates Final compound concentrations equal 500 nM, 50 nM, and 5 nM All samples completed in tnplicate with Control and IL-1 alone samples on each plate Plates are labeled and only the interior 24 wells of the plate are used On one of the plates, several columns are designated as IL-1 (no drug) and Control (no IL-1, no drug) These control columns are peπodically counted to monitor 35S-proteoglycan release. Control -20- and IL-1 media are added to wells (450 ul) followed by compound (50 ul) so as to initiate the assay Plates are incubated at 37°C, with a 5% C0 2 atmosphere At 40-50 % release (when CPM from IL-1 media is 4-5 times control media) as assessed by liquid scintillation counting (LSC) of media samples, the assay is terminated (9- 12 hours) Media is removed from all wells and placed in scintillation tubes Scinbllate is added and radioactive counts are acquired (LSC) To solubilize cell layers, 500 ul of papain digestion buffer (0 2 M Tπs, pH 7 0, 5 mM EDTA, 5 mM DTT, and 1 mg/ml papain) is added to each well Plates with digestion solution are incubated at 60°C overnight The cell layer is removed from the plates the next day and placed in scinbllation tubes Scintillate is then added, and samples counted (LSC) The percent of released counts from the total present in each well is determined Averages of the tπplicates are made with control background subtracted from each well The percent of compound inhibition is based on IL-1 samples as 0% inhibibon (100% of total counts) For admmistrabon to mammals, including humans, for the inhibibon of matnx metalloproteinases or the producbon of tumor necrosis factor (TNF), a vanety of convenbonal routes may be used including orally, parenterally and topically In general, the acbve compound will be administered orally or parenterally at dosages between about 0 1 and 25 mg/kg body weight of the subject to be treated per day, preferably from about 0 3 to 5 mg/kg However, some vaπabon in dosage will necessaπly occur depending on the condition of the subject being treated The person responsible for admmistrabon will, in any event determine the appropπate dose for the individual subject The compounds of the present invenbon can be administered in a wide vanety of different dosage forms, in general, the therapeubcally effective compounds of this invenbon are present in such dosage forms at concentrabon levels ranging from about 5 0% to about 70% by weight For oral admmistrabon, tablets containing vanous excipients such as microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine may be employed along with vaπous disintegrants such as starch (and preferably corn, potato or tapioca starch), alginic acid and certain complex silicates, together with granulation binders like polyvinylpyrro done, sucrose, gelation and acacia Additionally, lubπcabng agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tabletting purposes Solid compositions of a similar type may also be employed as fillers in gelatin capsules, preferred mateπals in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols When aqueous suspensions and/or elixirs are desired for oral adm istrabon, the acbve ingredient may be combined with vanous sweetening or -21- flavonng agents, coloπng matter or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glyceπn and vaπous like combinations thereof In the case of animals, they are advantageously contained in an animal feed or drinking water in a concentrabon of 5-5000 ppm, preferably 25 to 500 ppm For parenteral administration (intramuscular, intrapeπtoneal, subcutaneous and intravenous use) a steπle injectable solubon of the active ingredient is usually prepared Solutions of a therapeubc compound of the present invenbon in either sesame or peanut oil or in aqueous propylene glycol may be employed The aqueous solubons should be suitably adjusted and buffered, preferably at a pH of greater than 8, if necessary and the liquid diluent first rendered isotonic These aqueous solubons are suitable for intravenous injecbon purposes The oily solubons are suitable for intraarbcular, intramuscular and subcutaneous injecbon purposes The preparation of all these solubons under steπle conditions is readily accomplished by standard pharmaceubcal techniques well known to those skilled in the art In the case of animals, compounds can be administered intramuscularly or subcutaneously at dosage levels of about 0.1 to 50 mg/kg/day, advantageously 02 to 10 mg/kg/day given in a single dose or up to 3 divided doses For topical ocular admmistrabon, direct applicabon to the affected eye may be employed in the form of a formulabon as eyedrops, aerosol, gels or ointments, or can be incorporated into collagen (such as poly-2-hydroxyethylmethacrylate and co-polymers thereof), or a hydrophi c polymer shield The mateπals can also be applied as a contact lens or via a local reservoir or as a subconjuncbval formulation. For intraorbital admmistrabon a stenle injectable solution of the acbve ingredient is usually prepared Solubons of a therapeubc compound of the present invenbon in an aqueous solubon or suspension (particle size less than 10 micron) may be employed The aqueous solutions should be suitably adjusted and buffered, preferably at a pH between 5 and 8, if necessary and the liquid diluent first rendered isotonic Small amounts of polymers can be added to increase viscosity or for sustained release (such as cellulosic polymers, Dextran, polyethylene glycol, or alginic acid) These solubons are suitable for intraorbital injecbon purposes The preparabon of all these solubons under steπle conditions is readily accomplished by standard pharmaceubcal techniques well known to those skilled in the art. In the case of animals, compounds can be administered intraorbitally at dosage levels of about 0 1 to 50 mg/kg/day, advantageously 02 to 10 mg/kg/day given in a single dose or up to 3 divided doses The active compounds of the invention may also be formulated in rectal compositions such as supposrtoπes or retention enemas, e_g_, containing convenbonal suppository bases such as cocoa butter or other glyceπdes -22- For mtranasal administration or administration by mhalabon, the active compounds of the invention are conveniently delivered in the form of a solution or suspension from a pump spray container that is squeezed or pumped by the pabent or as an aerosol spray presentation from a pressunzed container or a nebulizer with the use of a suitable propellant, e g , dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas In the case of a pressuπzed aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount The pressurized container or nebulizer may contain a solubon or suspension of the acbve compound Capsules and cartridges (made, for example, from gelatin) for use in an inhaler or insufflator may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch. The present invenbon is illustrated by the following Preparations and Examples, but it is not limited to the details thereof. Example 1 4-[4-(4-FLUOROPHENOXY)BENZENESULFONYLAMIN01-TETRAHYDRO PYRAN-4-CARBOXYLIC ACID HYDROXYAMIDE (A) 4-[N-(Diphenylmethylene)amino1tetrahydropyran-4-carboxylic acid ethyl ester To a suspension of sodium hydride (6.56 grams. 0.164 mole) in ethylene glycol dimethyl ether (150 mL) at 0°C was added a solution of the N-(diphenylmethylene)glycine ethyl ester (20.60 grams, 0.07398 mole) in ethylene glycol dimethyl ether (50 mL) dropwise via addition funnel. A solution of 2-bromoethyl ether (23.21 grams, 0.090 mole) in ethylene glycol dimethyl ether (50 mL) was then added, in 10 mL portions over approximately 5 minutes, to the ethylene glycol dimethyl ether solution. The ice bath was removed and the reaction was stirred at room temperature for 16 hours. The mixture was diluted with diethyl ether and washed with water The aqueous layer was extracted with diethyl ether. The combined organic extracts were washed with brine, dπed over magnesium sulfate, and concentrated to afford a cloudy yellow oil (28.692 grams). Chromatography on silica gel eluting first with 4 L of 5% ethyl acetate/hexane followed by 4 liters of 10% ethyl acetate/hexane gave 4-[N-(diphenylmethylene)amιno]tetrahydropyran-4-carboxylic acid ethyl ester as a clear yellow oil (16.114 g, 64 %). HNMR (CDCIj) δ 7.58 (d, 2H), 7 36 (m, 4H), 7.28 (t, 2H), 7.08 (m, 2H), 3.99 (m, 2H), 3.70, (m, 2H), 3.66 (q, 2H), 2 10 (m, 2H), 1.99 (m, 2H), 1 08 (t, 3H) MS Atmospheric Pressure Chemical lonization Mass Spectra. 338 (M * +1) -23- (B) 4-Aminotetrahydropyran-4-carboxylic acid ethyl ester To a solubon of 4-[N-(dιphenylmethylene)amιno]tetrahydropyran-4-carboxylιc acid ethyl ester (16 0 grams, 0 047 mole) in diethyl ether (120 mL) was added 1M aqueous hydrochlonc acid solution (100 mL) The mixture was stirred vigorously at room temperature for 16 hours The layers were separated and the aqueous layer washed with diethyl ether The aqueous layer was brought to pH 10 with dilute aqueous ammonium hydroxide solution and extracted with dichloromethane The organic extract was dned over sodium sulfate and concentrated to give 4-amιnotetrahydropyran~4-carboxylιc acid ethyl ester (7 128 g, 71.7%) as an oil 1 HNMR (CDCIj) δ 4.15 (q, 2H), 3.82 (m, 2H), 3 62 (m, 2H), 2 07 (m, 2H), 1.60 (s. 2H), 1.44 (m, 2H), 1 24 (t, 3H) 13 CNMR (CDCI 3 ) d 176 48, 63.70, 61 09, 54.78, 35 05, 14.15. MS Atmospheric Pressure Chemical lonizabon Mass Spectra 210 (M + +1). (C) 4-[4-(4-Fluoropheπoxy)benzenesulfonylamino]tetrahydropyran-4- carboxylic acid ethyl ester To a solubon of 4-aminotetrahydropyran-4-carboxylιc acid ethyl ester (7.00 grams, 0.0404 mole) in N,N-dιmethylformamιde (40 mL) was added tnethylamine (5 94 mL. 0.043 mole). Solid 4-(4-fluorophenoxy)benzenesulfonyl chloπde (12 165 grams, 00424 mole) was added in portions. The resulting mixture was stirred at room temperature for 16 hours and then most of the solvent was removed by evaporation under vacuum. The residue was partitioned between saturated sodium bicarbonate solution and dichloromethane. The aqueous layer was extracted with dichloromethane The combined organic layers were washed with brine and dried over sodium sulfate. Evaporation of the solvent under vacuum provided crude 4-[4-(4-fluorophenoxy)benzenesulfonylamιno]tetrahydropyran-4-carboxylιc acid ethyl ester as an amber oil (21 05 grams). Flash chromatography on silica gel eluting with 25% ethyl acetate / hexane followed by 50% ethyl acetate / hexane provided 4-[4-(4- fluorophenoxy)benzenesulfonylamιno]tetrahydropyran-4-carboxylιc acid ethyl ester as an off- white crystalline solid (12 15 grams, 71%, mp 116-117°C). 1 HNMR (CDCI j ) δ 7.79 (d, 2H), 7.09 (t, 2H) 7.02 (m, 2H), 6.97 (d, 2H), 5.10 (s, 1H), 4.01 (q, 2H), 3 60 (m, 4H), 2.08 (m, 2H). 1.84 (br d, 2H). 1 23 (t, 3H). M S Atmospheπc Pressure Chemical lonizabon Mass Spectra: 424 (M + +1) (D) 4-[4-(4-Fluorophenoxy)-benzenesulfonylamino]tetrahydropyran-4- carboxylic acid Method A A solubon of 4-(4-(4-fluorophenoxy)benzenesulfonylamιnό]tetrahydropyran-4- carboxylic acid ethyl ester (12 1 grams, 0.0286 mole) in tetrahydrofuran (190 mL) was treated with aqueous 3 M sodium hydroxide solubon (95 mL, 0 286 mole) and stirred at room -24- temperature for 4 days The solvent was evaporated under vacuum and the residue partitioned between water and diethyl ether The aqueous layer was washed with diethyl ether, acidified to pH 1 with 3N aqueous hydrochloric acid solubon and extracted with dichloromethane After washing with water, the organic extract was dned over sodium sulfate, and concentrated to give 4-[4-(4-fluorophenoxy)-benzenesulfonylamιno]tetrahydropyran-4- carboxylic acid (11 241 grams, 99%) as a yellowish solid foam Method B A solubon of 4-[4-(4-fluorophenoxy)benzenesulfonylamιno]tetrahydropyran-4- carboxylic acid ethyl ester (34 19 grams, 0.807 mole) in ethanol (330 mL) was treated with aqueous 3 M sodium hydroxide solution (330 mL, 0.990 mole) and heated to reflux overnight The solvent was evaporated under vacuum and the residue partitioned between water and diethyl ether The aqueous layer was washed with diethyl ether, acidified to pH 1 with 3N aqueous hydrochloπc acid solubon and extracted with ethyl acetate. After washing with water, the organic extract was dried over sodium soulfate, and concentrated to give 4-[4-(4- fluorophenoxy)benzenesulfonylamιno]tetrahydropyran-4-carboxylic acid (31.26 grams, 98%) as a white crystalline solid. 'HNMR (CDCy δ 7.73 (d, 2H), 7 03 (t, 2H) 6.96 (m, 2H), 6 91 (d, 2H), 3.56 (m, 2H), 3.43 (br m, 3H), 2.01 (m, 2H), 1.80 (br d, 2H). MS Atmospheric Pressure Chemical lonizabon Mass Spectra 394 (M + -1 ) (-ion). (E) 4-[4-(4-Fluorophenoxy)benzenesulfonylamino]tetrahydropyran-4- carboxylic acid N-benzyloxyamide Diisopropyl ethylamine (3.89 grams, 0 030 mole) and (benzotrιazoM-yloxy)tπs- (dιmethylamιno)-phosphonιum hexafluorophosphate (13.27 grams, 0.030 mole) were added sequenbally to a solubon of 4-[4-(4-fiuorophenoxy)-benzenesulfonylamιno] tetrahydropyran-4- carboxylic acid (11.22 grams, 0 028 mole) in anhydrous N,N-dιmethylformamιde (140 mL) The resulbng solubon was sbrred at room temperature for 16 hours Additional diisopropyl ethylamine (4 0 mL, 0 051 mole) and O-benzyl hydroxylamme hydrochlonde (5 46 grams, 0.034 mole) were then added and the resulting mixture was sbrred at 60°C for 18 hours After concentration under vacuum, the residue was treated with 0 5N aqueous hydrochloric acid solution and extracted with ethyl acetate The organic extract was washed with saturated aqueous sodium bicarbonate solution, water, and brine. The solution was dned over magnesium sulfate, filtered and concentrated to one fourth original volume Addibon of an equal volume of hexane precipitated 4-[4-(4-fluorophenoxy)benzenesulfonylamιno]- tetrahydropyran-4-carboxylιc acid N-benzyloxyamide (11.595 g, 81.6%) as a white crystalline solid (mp 175-176°C). -25- 1 HNMR (CDCI 3 ) δ 7 76 (d, 2H), 7 35 (m, 5H), 7 05 (t, 2H) 6 96 (m 4H) 5 38 (br s, 1 H), 4 86 (s, 2H), 3 57 (m, 2H), 3 44 (m, 2H), 2 01 (m, 2H), 1 77 (br d, 2H), 1 54 (br s 1H) MS Atmospheric Pressure Chemical lonizabon 501 (M * +1) (F) 4-[4-(4-Fluorophenoxy)benzenesulfonylamino]-tetrahydropyran-4- carboxylic acid hydroxyamide Method A A solution of 4-[4-(4-fiuorophenoxy)benzenesulfonylamιno]tetrahydropyran-4- carboxylic acid N-benzyloxyamιde( 11 28 grams, 0 0225 mole) in ethyl acetate (600 mL) was treated with 5% palladium on baπum sulfate (5 0 grams) and hydrogenated in a Parr™ shaker at 3 atmospheres pressure for 18 hours After filtration through nylon (pore size 0 45 mm) to remove the catalyst, the filter pad was rinsed with methanol Combined filtrate and rinse were evaporated and the residue taken up in hot methanol Cooling afforded crude 4-[4-(4- fluorophenoxy)benzenesulfonylamιno]-tetrahydropyran-4-carboxylιc acid hydroxyamide (5 941 grams, 64%, mp 176-177°C) as a white crystalline solid The mother liquor was evaporated and the residue crystallized from 50% methanol dichloromethane to give additional 4-[4-(4- fluorophenoxy)benzenesulfonylamιno]-tetrahydropyran-4-carboxylιc acid hydroxyamide (0 660 grams, mp 184-185°C) as white needles The mother liquor was again evaporated and the residue crystallized from methanol/dichloromethane to give additional product (1 861 grams, mp 176-177°C) Recrystallizabon of the first lot from methanol/dichloromethane provided analytically pure 4-[4-(4-fluorophenoxy)benzenesulfonylamιno]tetrahydropyran-4-carboxylιc acid hydroxyamide (3 091 grams, mp 184-185°C) Method B Oxalyl chloπde (11 83 grams, 0 0932 mole, 1 1 eq ) and DMF (0 13 mL) were added to a sbrred suspension of the carboxylic acid (33 25 grams, 0 0841 mole) in dry methylene chloride (300 mL) at room temperature Some bubbling was observed The suspension, which slowly became a yellowish solution was sbrred overnight at room temperature Meanwhile, a solubon of hydroxylamme hydrochlonde (765 grams, 0 110 mole, 1 3 eq ) in dry pyπdine (51 4 mL, 0635 mole, 7 5 eq ) at 0°C was treated with chlorotπmethylsilane causing a white precipitate to form This suspension was stirred at room temperature overnight Both flasks were then cooled to 0°C and the solution of acid chloπde was added to the suspension of silylated hydroxylamme The resulbng mixture was stirred at 0°C for 1 hour and room temperature for 2 hours Added 1000 mL aqueous 2N HCI and stirred at room temperature for 1 hour The layers were separated, the aqueous layer was extracted , three times with ethylacetate (500 mL) Combined organic layers were washed with water and bπne and dned over magnesium sulfate, filtered and the volume of the filtrate reduced to 300 mL at which point a large amount of white crystalline solid had precipitated This was cooled overnight in a -26- refrigerator The solid was collected by vacuum filtrabon, rinsed with cold 1 1 ethylacetate/hexane and dried under high vacuum to give 30 311 grams of the desired hydroxamic acid (87 8%) as a white crystalline solid (mp 189-190°C) 'HNMR (d 6 DMSO) δ 1035 (br s, 1H), 868 (br s, 1H), 7 78 (br s, 1H), 7 74 (d, 2H), 7 26 (t, 2H), 7 16 (m, 2H), 7 04 (d, 2H), 3 40 (m, 2H), 3 31 (m. 2H), 1 78 (m, 4H) 13 CNMR (DMSO) δ 169 65, 160 66, 137 50, 129 39, 122 34, 122 25, 117 75, 117 44, 117 24, 62 94, 58 45, 33 34 MS Atmospheric Pressure Chemical lonizabon Mass Spectra 409 (M + -1) (- ion) Preparation A 4-(4-Fluorophenoxy)benzenesulfonyl chloride Chlorosulfonic acid (26 mL, 0 392 mole) was added dropwise to ice-cooled 4- fluorophenoxybenzene (36 9 grams, 0 196 mole) with mechanical sbrπng When addibon was complete, the mixture was sbrred at room temperature for 4 hours The mixture was then poured into ice water The product, 4-(4-fluorophenoxy)benzene-sulfonylchloπde (18 6 grams, 33%) was collected by filtrabon and dned in the air Preparation B Sodium 4- 3-methylbutoxy)benzenesutfonate A solubon of 4-hydroxybenzenesulfonιc acid (100 grams, 43 1 mmole) and sodium hydroxide (3 3 grams, 83 mmole) in water (40 mL) was mixed with a solubon of 1-ιodo-3- methylbutane (11 3 mL, 864 mmole) in isopropanol (60 mL) and the resulbng mixture was heated at reflux for 2 days The isopropanol was removed by evaporabon under vacuum The title compound, 10 0 grams (87%), was collected by filtrabon and washed with isopropanol Preparation C 4-(3-Methylbutoxy)benzenesulfonyl chloride A mixture of sodium 4-(3-methylbutoxy)benzenesulfonate (2 5 grams, 94 mmole), thionyl chlonde (10 mL), and 5 drops of N,N-dιmethylformamιde was heated at reflux for 5 hours After cooling, the excess thionyl chloπde was evaporated and the residue was taken up in ethyl acetate The solubon was cooled in an ice bath and water was added The organic phase was separated and washed with water and bπne After drying over sodium sulfate, the solvent was evaporated to afford the btie compound as an oil, 2 34 grams (95%) Preparation D Sodium 4-(2-cyclopentylethoxy)benzenesulfonate A solubon of 4-hydroxybenzenesulfonιc acid (6 5 grams, 28 2 mmole) and sodium hydroxide (2 2 grams, 55 mmole) in water (15 mL) was mixed with a solubon of 2- (bromoethyl)cyclopentane (15 0 grams, 84 7 mmole) in isopropanol (40 mL) and the resulbng mixture was heated at reflux for 2 days The isopropanol was removed by evaporabon under -27- vacuum. The titled compound, 4.7 grams (57%), was collected by filtration and washed with isopropanol. Preparation E 4-(3-Methylbutoxy)benzenesuffonyl chloride A mixture of sodium 4-(2-cydopentylethoxy)-benzenesulfonate (2.5 grams, 8.6 mmole), thionyl chloride (15 mL), and a few drops of N,N-dimethylformamide was heated at reflux for 5 hours. After cooling, the excess thionyl chloride was evaporated and the residue was taken up in ethyl acetate. The solubon was cooled in an ice bath and water was added. The organic phase was separated and washed with water and brine. After drying over sodium sulfate, the solvent was evaporated to afford the title compound as an oil, 2.24 grams (90%). Preparation F 4-Fluorobiphenylsulfonyl chloride Chtorosulfonic acid (8.7 mL, 0.13 mole) was added dropwise to 4-fluorobiphenyl (10.2 grams, 59 mmol) while stirring in an ice bath. Stirring was continued with ice cooling for 0.5 hours and then the reaction mixture was poured onto ice. The resulting white precipitate was collected by filtration and dissolved in chloroform. The chloroform solution was washed with water and brine, dried over magnesium sulfate and concentrated to afford a white solid. The desired product, 4-fluorobiphenylsurfbnyl chloride (4.3 grams, 27%), was separated from 4- fluorobiphenylsulfonic acid (an unwanted side product) by crystallization of the latter from ethyl acetate and crystallization of the remaining material from hexane. Preparation G Sodium 4-(4-fluorobenzyloxy)benzenesulfonate To a solution of 4-hydroxybenzenesulfonic acid (5.13 grams, 22.1 mmole) in 1N aqueous sodium hydroxide solution (23 mL) was added a solution of 4-fluorobenzylbromide (3.3 mL, 26.5 mmole) in ethanol (20 mL). The resulting mixture was heated at reflux for 2 days. Upon cooling and standing, a white solid precipitated. The precipitated product, sodium 4-(4- fluorobenzyloxy)benzenesulfonate, 4.95 grams (74%) was collected by filtration and washed with ethyl acetate and diethyl ether. Preparation H 4-<4-Fluorobenzyloxy)benzenesulfonyl chloride To a slurry of sodium 4-(4-fluorobenzyloxy)benzenesulfonate (0.5 grams, 1.64 mmole), in methylene chloride (5 mL) was added phosphorus pentachloride (275 mg. 1.31 mmole). The resulting mixture was heated at reflux for 7 hours. After cooling in an ice bath and quenching with water (15 mL), the mixture was extracted with ethyl acetate. The organic phase was washed with brine, dried over sodium sulfate, and concentrated to afford 4-(4- fluorobenzyloxy)benzenesuffonyl chloride a white solid (130 mg, 26%). -28- Preparation I 4-(4-Chlorophenoxy)benzenesulfonyl chloride Chlorosulfonic acid (9 7 mL, 0.147 mole) was added dropwise to 4- chlorophenoxy benzene (12 6 mL, 73.4 mmole) at room temperature with sbmng When addition was complete, the mixture was stirred at room temperature for 1 hour and then poured into ice water. The solid was collected by filtrabon, dned in the air, and recrystallized from petroleum ether and ethyl acetate to give 4-(4-chlorophenoxy)benzenesulfonylchloride (743 grams, 33%)

Claims: -29- CLAIMS A compound of the formula O SO-Q or the pharmaceutically acceptable salts thereof, wherein Q is (C,-C 6 )alkyl, (C 6 -C 10 )aryl, (C 2 -C 9 )heteroaryl, (Ce-CioJaryloxy^-CeJslkyl, (C 6 - C l0 )aryloxy(C 6 -C 10 )aryl, (C 6 -Cιo)aryloxy(C 2 -C 9 )heteroaryl, (C 6 -C, 0 )aryI(C,-C 6 )alkyl, (C 6 - C 10 )aryl(C 5 -C 10 )aryl, (C 6 -C 10 )aryl(C 2 -C 9 )heteroaryl, (Ce-C^ary Cβ-C^ary C^alkyl, (C 6 - Cιo)3ryl(C 6 -Cιo)aryl(C 6 -C,o)aryl, (C 6 -Cιo)3ryl(C 6 -Cιo)aryl(C 2 -C 9 )hetero3ryl, (C 2 -C 9 )heteroaryl(C,- C 6 )alkyl, (C 2 -C 9 )heteroaryl(C 6 -C 10 )aryl, (C 2 -C 9 )heteroaryl(C 2 -C 9 )heteroaryl, (C 6 -C,o)aryl(C,- C 6 )alkoxy(C,-C 6 )alkyl, (C 6 -C,o)aryl(C 1 -C 6 )alkoxy(C 6 -C, 0 )aryl, (C 6 -C, 0 )aryl(C,-C 6 )alkoxy(C 2 - Cgjheteroaryl, (C 2 -C 9 )hetero3ryloxy(Cι-C 6 )3lkyl, (C 2 -C 9 )hetero3ryloxy(C e -Cιo)aryl, (C 2 - C 9 )heteroaryloxy(C r C 9 )heteroaryl, (Cj-CgJheteroaryl^-CeJalkoxy^-CeJalkyl, (C 2 - C 9 )heteroaryl(Ci-C 6 )alkoxy(C 6 -C, 0 )aryl or (C 2 -C 5 )heteroaryl(C 1 -C 6 )alkoxy(C 2 -C 9 )heteroaryl; wherein each (C 6 -C 10 )aryl or (C 2 -C 9 )heteroaryl moieties of said (C 6 -C, 0 )aryl, (C 2 - C 9 )hetero3ryl, (C 6 -C, 0 )3ryloxy(C,-C 6 )3lkyl, (C 6 -Cio)aryloxy(C 6 -C,o)aryl, (C 6 -C 10 )3ryloxy(C 2 - C 9 )heteroaryl, (C 6 -C,o)aryl(Ci-C 6 )alkyl, (C 6 -C 10 )aryl(C 6 -C 10 )aryl, (C 6 -C, 0 )aryl(C 2 -C 9 )heteroaryl, (C 6 -C,o)3ryl(C 6 -C,o)aryl(C,-C 6 )alkyl, (C 6 -C,o)aryl(C 6 -Cio)aryl(C 6 -C,o)aryl, (C 6 -C 10 )aryl(C 6 - C^ary Cz-CgJheteroaryl, (C 2 -C 9 )heteroaryl(C,-C 6 )alkyl, (C 2 -C 9 )heteroaryl(C 6 -C, 0 )aryl, (C 2 - CgJheteroary Cz-CgJheteroaryl, (C f s-CioJary Ci-C^slkoxyfCrCβJal yl, (C 6 -C 10 )aryl(C,- C 6 )alkoxy(C 3 -C, 0 )aryl, (Cβ-Cι 0 )aryl(C,-C β )3lkoxy(C 2 -C 9 )heteroaryl, (C 2 -C 9 )hetero3ryloxy(C,- C 6 )alkyl, (C 2 -C 9 )heteroaryloxy(C 6 -C 10 )3ryl, (C 2 -C 9 )hetero3ryloxy(C 2 -C 9 )hetero3ryi, (C 2 - C 9 )heteroaryl(C,-C 6 )alkoxy(C,-C 6 )alkyl, (C 2 -C 9 )heteroaryl(Cι-C 6 )alkoxy(C 6 -C, 0 )aryl or (C 2 - C 9 )hetero3ryl(C,-C 6 )3lkoxy(C 2 -C 9 )heteroaryl is optionally substituted on any of the ring carbon atoms capable of forming an additional bond by one or more substituents per ring independently selected from fluoro, chloro, bromo, (C,-C 6 )alkyl, (C,-C 6 )alkoxy, perfluoro(C,-C 3 )alkyl, perfluoro(C,-C 3 )alkoxy and (C 6 -C, 0 )aryloxy; or a pharmaceutically acceptable salt thereof. 2. A compound according to claim 1, wherein Q is optionally substituted (C 6 - CoJsryl, (C 6 -C,o)aryl(C 6 -C, 0 )aryl, (C 6 -C, 0 )aryloxy(C 6 -Cιo)aryl, (C 6 -C, 0 )aryloxy(C 2 -C 9 )heteroaryl. (C 2 -C 9 )heteroaryl, (C 2 -C 9 )hetero3ryl(C 2 -C 9 )hetero3ryl, (C 6 -C,o)aryl(C 2 -C 9 )heteroaryl, (C 2 -C 9 )- -30- heteroaryl(C 6 -C 10 )aryl, (C 2 -C 9 )heteroaryloxy(C 6 -C 10 )aryl, (Cg-C^aryKC-CeJalkoxyfCe-Cio^aryl, or (C 2 -C 9 )heteroaryl(C 1 -C 6 )alkoxy(C 6 -C,o)aryl 3 A compound according to claim 1, wherein Q is opbonally substituted (C 6 - C 10 )aryloxy(C 6 -C 10 )aryl 4 A compound according to claim 3, wherein the (C 6 -C. 0 )aryloxy πng of said (C 6 - C 1 o)aryloxy(C 6 -Cιo)3ryl group is optionally mono-substituted in the 4-posιtιon of the πng 5 A compound according to clsim 1 , wherein said compound is selected from the group consisting of 4-[4-(4-fluorophenoxy)benzenesulfonylamιno]tetrahydropyran-4-carboxylιc acid hydroxyamide, 4-[4-(4-chlorophenoxy)benzenesulfonylamιno]tetrahydropyran-4-carboxylιc acid hydroxyamide, 4-[4-(phenoxy)benzenesulfonylamιno]tetrahydropyran-4-carboxylιc acid hydroxyamide, 4-[4-(4-pyπdyloxy)benzenesulfonylamιno]tetrahydropyran-4-carboxylιc acid hydroxyamide, 4-[4-(4-fluorophenyl)benzenesulfonylamιno]tetr3hydropyran-4-carboxylιc acid hydroxyamide, 4-[4-(4-fluorophenylmethoxy)benzenesulfonylamιno]tetrahydropyran-4-carboxylιc acid hydroxyamide, (phenylmethoxy)benzenesulfonylamino]tetrahydropyran-4-carboxylic acid hydroxyamide, and 4-[4-(4-Fluorophenylethoxy)benzenesulfonylamιno]tet/ahydropyran-4-carboxylιc acid hydroxyamide, 6 A pharmaceubcal composibon for the treatment of a condition selected from the group consisting of arthπtis (including osteoarthnbs and rheumatoid arthπbs), inflammatory bowel disease, Crohn's disease, emphysema, chronic obstructive pulmonary disease, Alzheimer's disease, organ transplant toxicity, cachexia, allergic reactions, allergic contact hypersensitivity, cancer, tissue ulcerabon, restenosis, peπodontal disease, epidermolysis bullosa, osteoporosis, loosening of artificial joint implants, atherosclerosis (including atherosclerotic plaque rupture). aorbc aneurysm (including abdominal aorbc aneurysm and brain aorbc aneurysm), congesbve heart failure, myocardial infarction, stroke, cerebral ischemia, head trauma, spinal cord injury, neuro-degenerabve disorders (acute and chronic), autoimmune disorders, Hunbngton's disease, Parkinson's disease, migraine, depression, penpheral neuropathy, pain, cerebral amyloid angiopsthy, nootropic or cognition enhancement amyotrophic lateral sclerosis, multiple sclerosis, ocular angiogenesis, comeal injury, macular degenerabon, abnormal wound healing, -31- bums, diabetes, tumor invasion, tumor growth, tumor metastasis, comeal scamng, scleπtis, AIDS, sepsis and septic shock in a mammal, including a human, compnsmg an amount of a compound of claim 1 effecbve in such treatment and a pharmaceutically acceptable earner 7 A method for treating a condition selected from the group consisting of arthπbs (including osteoarthnbs and rheumatoid arthnbs), inflammatory bowel disease, Crohn's disease, emphysema chronic obstructive pulmonary disease, Alzheimer's disease, organ transplant toxicity, cachexia, allergic reactions, allergic contact hypersensitivity, cancer, tissue ulcerabon, restenosis, peπodontal disease, epidermolysis bullosa, osteoporosis, loosening of artificial joint implants, atherosclerosis (including atherosclerotic plaque rupture), aortic aneurysm (including abdominal aortic aneurysm and brain aortic aneurysm), congestive heart failure, myocardial infarction, stroke, cerebral ischemia, head trauma, spinal cord injury, neuro-degenerative disorders (acute and chronic), autoimmune disorders, Huntington's disease, Parkinson's disease, migraine, depression, peπpheral neuropathy, pain, cerebral amyloid angiopathy, nootropic or cognibon enhancement, amyotrophic lateral sclerosis, multiple sclerosis, ocular angiogenesis, comeal injury, macular degenerabon, abnormsl wound heslmg, bums, diabetes, tumor invasion, tumor growth, tumor metastasis, comeal scamng, scleπbs, AIDS, sepsis and sepbc shock in a mammal, including a human, compnsmg administeπng to said mammal an amount of a compound of claim 1 , effecbve in treating such a condition 8 A pharmaceutical composition for the treatment of a condition which can be treated by the inhibition of matπx metalloproteinases in a mammal, including a human, compπsing an amount of a compound of claim 1 effecbve in such treatment and a pharmaceutically acceptable carrier 9 A pharmaceutical composition for the treatment of a condition which can be treated by the inhibition of a mammalian reprolysm in a mammal, including a human, compπsing an amount of a compound of claim 1 effective in such treatment and a pharmaceutically acceptable carrier 10 A method for the inhibition of matπx metalloproteinases in a mammal, including a human, compπsing administeπng to said mammal an effective amount of a compound of claim 1 11 A method for the inhibition of a mammalian reprolysm in a mammal, including a human, compnsmg administeπng to said mammal an effecbve amount of a compound of claim 1

Inventors: REITER LAWRENCE ALAN, REITER, LAWRENCE, ALAN
Applicants: PFIZER PROD INC, REITER LAWRENCE ALAN, PFIZER PRODUCTS INC., REITER, LAWRENCE, ALAN
Application year: 1999
Main classification: C07D309
IPC codes: A61K31, A61P1, A61P3, A61P9, A61P11, A61P17, A61P19, A61P25, A61P27, A61P29, A61P31, A61P35, A61P37, A61P43, C07D309, C07D405